Evidence map›Paper›PMID 33045187›Full record

ArticleThe Lancet. Infectious diseases2021

Beyond COVID-19-a paradigm shift in infection management?

Maria J G T Vehreschild, Evelina Tacconelli, Christian G Giske, Andreas Peschel

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in The Lancet. Infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Maria J G T VehreschildGerman Centre for Infection Research, Partner Site Bonn-Cologne, Germany; University of Cologne, Department I of Internal Medicine, Cologne, Germany; Department of Internal Medicine, Infectious Diseases, Goethe University Frankfurt, Frankfurt, Germany.
Evelina TacconelliInfectious Diseases Unit, Department of Diagnostics and Public Health, Verona University Hospital, Verona, Italy; Cluster of Excellence EXC2124 "Controlling Microbes to Fight Infections", University of Tübingen, Tübingen 72076, Germany; German Centre for Infection Research, Partner Site Tübingen, Germany.
Christian G GiskeDivision of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden; Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Andreas PeschelInterfaculty Institute of Microbiology and Infection Medicine, University of Tübingen, Tübingen 72076, Germany; Cluster of Excellence EXC2124 "Controlling Microbes to Fight Infections", University of Tübingen, Tübingen 72076, Germany; German Centre for Infection Research, Partner Site Tübingen, Germany. Electronic address: andreas.peschel@uni-tuebingen.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

SARS-CoV-2COVID-19Cross InfectionHumans

Identifiers

PMID33045187
PMCPMC7546645

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.